Ferring Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
as on 14-12-2024
- Paid Up Capital ₹ 1.26 Cr
as on 14-12-2024
- Company Age 27 Year, 5 Months
- Last Filing with ROC 31 Dec 2023
- Open Charges ₹ 1.20 Cr
as on 14-12-2024
- Revenue 19.23%
(FY 2022)
- Profit -26.49%
(FY 2022)
- Ebitda -32.64%
(FY 2022)
- Net Worth 9.51%
(FY 2022)
- Total Assets 26.88%
(FY 2022)
About Ferring Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 December 2023. It's a company limited by shares with an authorized capital of Rs 4.00 Cr and a paid-up capital of Rs 1.26 Cr.
The company currently has active open charges totaling ₹1.20 Cr.
Didier Page and Sudheendra Kulkarni serve as directors at the Company.
- CIN/LLPIN
U74140MH1997FTC109220
- Company No.
109220
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
04 Jul 1997
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Dec 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Ferring Pharmaceuticals Private Limited offer?
Ferring Pharmaceuticals Private Limited offers a wide range of products and services, including Diabetes Medicine, Desmopressin Acetate Tablet.
Who are the key members and board of directors at Ferring Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sudheendra Kulkarni  | Managing Director | 17-May-2021 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Didier Page  | Director | 01-Apr-2021 | Current |
Financial Performance of Ferring Pharmaceuticals.
Ferring Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 19.23% increase. The company also saw a substantial fall in profitability, with a 26.49% decrease in profit. The company's net worth moved up by a moderate rise of 9.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ferring Pharmaceuticals?
In 2022, Ferring Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Hongkong And Shanghai Banking Corporation Limited Creation Date: 04 Jan 2019 | ₹2.00 M | Open |
State Bank Of India Creation Date: 26 Feb 2000 | ₹1.00 Cr | Open |
How Many Employees Work at Ferring Pharmaceuticals?
Ferring Pharmaceuticals has a workforce of 168 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ferring Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ferring Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
